UMS increases lithotripsy business

USMD Health Systems has sold US Lithotripsy LP to United Medical Systems, Inc. (UMS), a subsidiary of private investment firm New State Capital Partners. UMS provides turnkey mobile lithotripsy, laser and stereotactic breast biopsy services to patients at 850 healthcare facilities in the U.S., Canada and Latin America. The acquired company, US Lithotripsy, is a provider of lithotripsy services at facilities in Arizona, Arkansas, Colorado, Missouri, Oklahoma and Texas. It performs over 12,000 ESWL (Extracorporeal Shock Wave Lithotripsy) procedures annually. With its acquisition by UMS, US Lithotripsy will add more than 100 hospitals, ambulatory surgical centers and other sites of service in... Read More »

Agenus on a roll in 2015

Agenus Inc., an immunology company developing novel checkpoint modulators, vaccines and adjuvants to treat cancer, acquired Phoslmmune Inc. last week. Phoslmmune is an immunotherapy company that has discovered a new portfolio of cancer neoantigens. Its equity holders will receive an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing, plus milestone payments of up to $35 million in cash and/or stock. This acquisition gives Agenus the capacity to expediate the development of new cancer vaccines and other single-agent immuno-oncology approaches, as well as combination therapies. And the deal most likely caps a healthy year for Agenus, which... Read More »

Pharma’s Big Year in M&A

With one week to go in 2015, there are still a few big pharmaceutical deals in the works. Shire plc (NASDAQ: SHPG) is now in friendly talks to take over Baxalta International Inc. (NYSE: BXLT) for a price rumored to be above $30 billion. By who’s waiting for 2016? Here is a preliminary tally of the year in pharmaceutical M&A, and how it compares to previous years. Spoiler alert: 2015 is another record year in dollar value. Pharmaceutical M&A, 2011 to 2015* 20112012201320142015 Deal volume115103150188167 % change11%-10%46%25%-11% Deal value$44.1 billion$38.1 billion$66.7 billion$213.3 billion$297.4 billion % change11%-14%76%219%40% *= thru Dec.... Read More »